Novimmune Completes CHF30 Million Funding Round12.01.2016 13:26
Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory and rare diseases, immune-related disorders and cancer, announced it has completed a CHF30 million ($29.8 million) funding round with existing shareholders.
The round is characterised by a broad participation from the shareholder base. Novimmune will use the funds to invest in developing the drug pipeline, including NI-0501 for Hemophagocytic Lymphohistiocytosis (HLH).
“We are delighted to have completed a CHF30 million funding round driven by major commitments from our lead investors that secured broad participation from our existing shareholder base,” said Novimmune Chairman and Chief Executive Officer Eduard Holdener. “This support from our shareholders demonstrates the confidence they have in the strength of our pipeline and in the future of the Company. We remain committed to further developing novel medicines to provide improved treatment options for patients suffering from rare and devastating diseases like Hemophagocytic Lymphohistiocytosis (HLH), as well as autoimmune and inflammatory diseases, and cancer.”
Novimmune SA is a Swiss biopharmaceutical company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer. The company is headquartered in Geneva.